Normal Goat Control IgG

 
Normal Goat Control IgG Antibody Product Information
 
Antibody Type : Goat Polyclonal Antibody
Ig Type : Goat IgG
Reactivity : Goat
Formulation : 140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH7.4
Source/purification: The antibody was isolated from normal Goat serum and purified by protein A.
Specificity : The purified antibody is not directed against any known antigen. (No known specificity)
 
Normal Goat Control IgG Usage Guide
 
Application : ELISA, WB, IHC, IP
This control antibody must be diluted to the same concentration as the specific primary antibody used for analysis.
Storage : This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
 
Browse Additional IgG Control Reagents by species
 
Additional Primary & Secondary Antibody Reagents
 
Normal Goat Control IgG Background

Normal Goat Control IgG is essential for ELISA, Western Blot (WB), Immunohistochemistry (IHC) and Immunoprecipitation (IP) experiments. It's purpose is to estimate that the proteins stained in the experiment result are due to the specific interaction with the antibody. Some people use specific primary antibody alone. This does not consider of those proteins that may bind to regions of the immunoglobulin distinct from the specific antigen binding sites. This Non-Specific binding is due to Fc receptor binding or other protein-protein interactions.The best way is to use isotype-matched control for the experiment. The IgG isotyping control should have the same immunoglobulin subtype and be used at the same concentration as the specific detection antibody. Sino Biological has a very good selection of control IgGs and the quality is excellent.

 
References
  1. Amigorena S. et al., 1998, J Exp Med. 187 (4): 505-15.
  2. Hurez V. et al., 1993, Eur J Immunol. 23 (4): 783-9.
  3. Johnson RJ. et al., 1992, J Exp Med. 175 (5): 1413-6.
 
  • Disparate Regulatory Mechanisms Control Fat3 and P75 NTR Protein Transport through a Conserved Kif5-Interaction Domain
    Author
    Cheng, H;Garcia, JB;Birkness, JE;Trinidad, JC;Deans, MR;
    Year
    2016
    Journal
    PloS one
    Application
    IP
  • The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression
    Author
    Wang, L;Meng, Y;Xu, JJ;Zhang, QY;
    Year
    2018
    Journal
    Mol. Cancer Res.
    Application
    ChIP
Add to Cart Successfully Add to Cart Failed